|Positive WB detected in||HeLa cells, BxPC-3 cells, human brain tissue, human placenta tissue, K-562 cells, MCF-7 cells, mouse testis tissue|
|Positive IP detected in||mouse testis tissue|
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Sample-dependent, check data in validation data gallery|
10696-1-AP targets FBXO7 in WB, IP, CoIP,ELISA applications and shows reactivity with human, mouse samples.
|Tested Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||FBXO7 fusion protein Ag1035|
|Full Name||F-box protein 7|
|Calculated molecular weight||58.5 kDa|
|Observed molecular weight||58.5 kDa|
|GenBank accession number||BC008361|
|Gene ID (NCBI)||25793|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
FBXO7, also named as FBX7, is a substrate recognition component of a (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. FBXO7 recognizes BIRC2 and DLGAP5. It function in phosphorylation-dependent ubiquitination.
Chemical inhibition of FBXO7 reduces inflammation and confers neuroprotection by stabilizing the mitochondrial kinase PINK1.
Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells.